Antengene’s US$1.2bn UCB deal enters human testing, but can ATG-201 control autoimmune disease?
Antengene begins Phase 1 testing of ATG-201 under its UCB partnership, with safety, B-cell depletion and autoimmune efficacy still to be established.
Pharma & Biotech